These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Falsely low serum prolactin in two cases of invasive macroprolactinoma. Schöfl C, Schöfl-Siegert B, Karstens JH, Bremer M, Lenarz T, Cuarezma JS, Samii M, von zur Mühlen A, Brabant G. Pituitary; 2002; 5(4):261-5. PubMed ID: 14558675 [Abstract] [Full Text] [Related]
6. Increased body weight associated with prolactin secreting pituitary adenomas: weight loss with normalization of prolactin levels. Greenman Y, Tordjman K, Stern N. Clin Endocrinol (Oxf); 1998 May; 48(5):547-53. PubMed ID: 9666865 [Abstract] [Full Text] [Related]
8. The effect of quinagolide and cabergoline, two selective dopamine receptor type 2 agonists, in the treatment of prolactinomas. Di Sarno A, Landi ML, Marzullo P, Di Somma C, Pivonello R, Cerbone G, Lombardi G, Colao A. Clin Endocrinol (Oxf); 2000 Jul; 53(1):53-60. PubMed ID: 10931080 [Abstract] [Full Text] [Related]
9. Giant pituitary prolactinoma with falsely low serum prolactin: the pitfall of the "high-dose hook effect": case report. Barkan AL, Chandler WF. Neurosurgery; 1998 Apr; 42(4):913-5; discussion 915-6. PubMed ID: 9574657 [Abstract] [Full Text] [Related]
10. Concomitant Cushing's Disease and Marked Hyperprolactinemia: Response to a Dopamine Receptor Agonist. Shiraishi J, Koyama H, Shirakawa M, Ishikura R, Okazaki H, Kurajoh M, Shoji T, Moriwaki Y, Yamamoto T, Namba M. Intern Med; 2016 Apr; 55(8):935-41. PubMed ID: 27086808 [Abstract] [Full Text] [Related]
11. Serum prolactin concentration at presentation of non-functioning pituitary macroadenomas. Behan LA, O'Sullivan EP, Glynn N, Woods C, Crowley RK, Tun TK, Smith D, Thompson CJ, Agha A. J Endocrinol Invest; 2013 Apr; 36(7):508-14. PubMed ID: 23385474 [Abstract] [Full Text] [Related]
12. Basal, pulsatile, entropic, and 24-hour rhythmic features of secondary hyperprolactinemia due to functional pituitary stalk disconnection mimic tumoral (primary) hyperprolactinemia. Veldman RG, Frölich M, Pincus SM, Veldhuis JD, Roelfsema F. J Clin Endocrinol Metab; 2001 Apr; 86(4):1562-7. PubMed ID: 11297584 [Abstract] [Full Text] [Related]
14. Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia. Colao A, Di Sarno A, Cappabianca P, Di Somma C, Pivonello R, Lombardi G. N Engl J Med; 2003 Nov 20; 349(21):2023-33. PubMed ID: 14627787 [Abstract] [Full Text] [Related]
15. Nephrotic-range proteinuria in a patient with a giant prolactinoma. Heras M, Iglesias P, Fernández-Reyes MJ, Sánchez R, Jiménez MJ, Muñoz H, Tajada P, Duarte J. Am J Kidney Dis; 2008 Jun 20; 51(6):1025-8. PubMed ID: 18455849 [Abstract] [Full Text] [Related]
18. Ropinirole for the Treatment of Hyperprolactinemia: A Dose-Escalation Study of Efficacy and Tolerability. Heneghan LJ, Tsang A, Dimino C, Khandji AG, Panigrahi SK, Page-Wilson G. J Clin Endocrinol Metab; 2024 Jan 18; 109(2):e667-e674. PubMed ID: 37715962 [Abstract] [Full Text] [Related]